— Technology currently being evaluated for the
treatment of ovarian cancer in Phase 1 clinical trial —
SAN
JOSE, Calif., July 11,
2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that the
Canadian Intellectual Property Office has issued Canadian Patent
2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell
(CAR-T) cancer treatment technology, which has been licensed from
The Wistar Institute and is being developed in partnership with
Moffitt Cancer Center.
The patent, entitled "Methods and Compositions for Treating
Cancer," covers a nucleic acid that encodes a chimeric protein
whose domains can be used to treat certain types of cancer by
binding to specific hormone receptors and activating T cells. The
patent was invented by Drs. Jose
Conejo-Garcia and Alfredo
Perales-Puchalt, both formerly of The Wistar Institute, to
which the patent is assigned, along with Anixa's majority-owned
subsidiary, Certainty Therapeutics, Inc., which is the exclusive,
world-wide licensee.
Dr. Amit Kumar, Chairman and CEO
of Anixa, stated, "We are pleased that our CAR-T technology has
received additional intellectual property protection in a market
outside the U.S. Our novel CAR-T technology takes advantage of
specific hormone-to-hormone receptor biology to address
malignancies and has the potential to be the first successful CAR-T
therapy against solid tumors. While our initial focus is on the
treatment of ovarian cancer — with a Phase 1 clinical trial
currently ongoing — the technology covered by the patent has broad
application and could potentially also be used to treat other solid
tumors by exploiting an anti-angiogenesis mechanism of action."
About Anixa's CER-T Approach (Follicle Stimulating Hormone
Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen receptor T-cell (CAR-T) technology
approach is an autologous cell therapy comprised of engineered
T-cells that target the follicle stimulating hormone receptor
(FSHR). FSHR is found at immunologically relevant levels
exclusively on the granulosa cells of the ovaries. Since the target
is a hormone receptor and the target-binding domain is derived from
its natural ligand, this technology is known as CER-T (chimeric
endocrine receptor T-cell) therapy, a new type of CAR-T.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic
portfolio consists of an ovarian cancer immunotherapy program that
uses a novel type of CAR-T known as chimeric endocrine receptor
T-cell (CER-T) technology, and is being developed in collaboration
with Moffitt Cancer Center. The Company's vaccine portfolio
includes a novel vaccine being developed in collaboration with
Cleveland Clinic to prevent breast cancer – specifically triple
negative breast cancer (TNBC), the most lethal form of the disease
– as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more,
visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-canadian-patent-for-its-car-t-cancer-therapy-technology-301873707.html
SOURCE Anixa Biosciences, Inc.